SOLID CARCINOMA

This is the first human trial of an experimental cancer drug called DM005. The study aims to find a safe and effective dose for patients with advanced solid tumors like lung and head/neck cancer that have stopped responding to standard treatments. Researchers will give the drug t…

This study is testing the safety of a new two-drug combination (avutometinib and defactinib) for children and young adults (ages 3-30) whose solid tumors have come back or stopped responding to standard treatments. The main goal is to find the highest dose that is safe and causes…

This study is testing a new oral drug, S241656, alone and in combination with other cancer therapies. It aims to find a safe and effective dose for adults with advanced cancers, including lung, pancreatic, and colorectal cancers, that have specific genetic mutations like KRAS or …

This study is testing whether a fecal microbiota transplant (FMT) can help patients with advanced solid cancers who have stopped responding to a common type of immunotherapy. The goal is to see if changing the gut bacteria with FMT can make the cancer respond again to the drug ni…

This early-stage study is testing a new cancer drug called INV-1120, both by itself and combined with an existing immunotherapy (pembrolizumab), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe dose levels a…

This is the first human study of an experimental cancer drug called DM002 for people with advanced solid tumors including ovarian, prostate, endometrial, and colorectal cancers. The study has two parts: first finding the safest dose, then testing that dose to see how well it work…

This study is testing a new type of imaging scan to see if it can better detect and monitor many different solid tumors. The scan uses a special tracer that attaches to a protein called Trop2, which is often found on cancer cells. Researchers will compare this new scan to standar…

This study is testing whether a new blood test can predict which cancer patients are most likely to develop dangerous blood clots. Researchers will track 200 patients with lung, pancreatic, stomach, or brain cancer for one year after they start treatment, taking monthly blood sam…